Acute Myeloid Leukemia
Courtney DiNardo, MD
Biomarkers and Impact on Use of Targeted Agents in Acute Leukemias, Including FLT3 Inhibitors, IDH Inhibitors, and Others #BeyondASH21
More from Acute Myeloid Leukemia
Selina Luger, MD, FRCPC
Recently Presented Data of Clinical Trials in Patients with AML or ALL #BeyondASH21
Eunice Wang, MD
How to Incorporate Emerging Novel Agents and Combinations in the R/R Setting for AML and ALL #BeyondASH21
